Scholarlink

<p>Smith-Magenis syndrome (SMS) and Potocki-Lupski syndrome (PTLS) are reciprocal genomic disorders caused by deletions and duplications of the 17p11.2 chromosomal region, respectively. This study aimed to identify and validate DNA methylation episignatures specific to SMS and PTLS, and to investigate their reciprocal relationship and shared molecular features with other neurodevelopmental disorders. Genome-wide DNA methylation was analyzed in individuals with an SMS (<i>n</i> = 26) or PTLS (<i>n</i> = 27) phenotype associated with copy number variation, and SMS patients with <i>RAI1</i> sequence variants using the Infinium EPIC array. Differentially methylated CpG sites were identified and used to develop support vector machine (SVM)-based classifiers, which demonstrated high sensitivity and specificity for both syndromes. The analysis revealed a mirror-like episignature, with SMS showing predominant hypomethylation and PTLS displaying hypermethylation at shared loci. Functional correlation with other neurodevelopmental disorders highlighted significant overlap with known episignatures, including those associated with <i>MEF2C</i>-related disorders. Notably, individuals with <i>RAI1</i> sequence variants did not exhibit the same DNA methylation patterns, suggesting that the epigenetic alterations are primarily driven by copy number changes. These findings establish SMS and PTLS as distinct yet interconnected epigenetic entities, offering valuable diagnostic biomarkers and insights into the molecular pathophysiology of 17p11.2-associated neurodevelopmental disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DNA methylation episignature for Smith-Magenis and Potocki-Lupski syndromes: a mirror perspective

  • 期刊论文

  • 发表日期：

    2025年9月30日

查看全文
  • Liselot van der Laan,
  • Karim Karimi,
  • Kathleen Rooney,
  • Mariëlle Alders,
  • Alfredo Brusco,
  • Amaia Lasa-Aranzasti,
  • Nicola Brunetti-Pierri,
  • Anna M. Cueto-Gonzalez,
  • Barbara R. DuPont,
  • Gerarda Cappuccio,
  • Christele Dubourg,
  • David Everman,
  • Vincent Gatinois,
  • Benjamin Ganne,
  • David Genevieve,
  • Giovanni Battista Ferrero,
  • Marlies Kempers,
  • Michael A. Levy,
  • Marcello Niceta,
  • Antonio Novelli,
  • Valeria Orlando,
  • Sylvie Odent,
  • Wesley G. Patterson,
  • Abeltje M. Polstra,
  • Tony Roscioli,
  • Nathalie Ruiz-Pallares,
  • Quentin Sabbagh,
  • Slavica Trajkova,
  • Marco Tartaglia,
  • Matthew A. Tedder,
  • Annick Toutain,
  • Udo Koehler,
  • Irena Valenzuela,
  • Johanna M. van Hagen,
  • Anne-Marie van der Kevie-Kersemaekers,
  • Peter Henneman,
  • Marcel M. A. M. Mannens,
  • Bekim Sadikovic,
  • Mieke M. van Haelst

摘要

Smith-Magenis syndrome (SMS) and Potocki-Lupski syndrome (PTLS) are reciprocal genomic disorders caused by deletions and duplications of the 17p11.2 chromosomal region, respectively. This study aimed to identify and validate DNA methylation episignatures specific to SMS and PTLS, and to investigate their reciprocal relationship and shared molecular features with other neurodevelopmental disorders. Genome-wide DNA methylation was analyzed in individuals with an SMS (n = 26) or PTLS (n = 27) phenotype associated with copy number variation, and SMS patients with RAI1 sequence variants using the Infinium EPIC array. Differentially methylated CpG sites were identified and used to develop support vector machine (SVM)-based classifiers, which demonstrated high sensitivity and specificity for both syndromes. The analysis revealed a mirror-like episignature, with SMS showing predominant hypomethylation and PTLS displaying hypermethylation at shared loci. Functional correlation with other neurodevelopmental disorders highlighted significant overlap with known episignatures, including those associated with MEF2C-related disorders. Notably, individuals with RAI1 sequence variants did not exhibit the same DNA methylation patterns, suggesting that the epigenetic alterations are primarily driven by copy number changes. These findings establish SMS and PTLS as distinct yet interconnected epigenetic entities, offering valuable diagnostic biomarkers and insights into the molecular pathophysiology of 17p11.2-associated neurodevelopmental disorders.